MARLBOROUGH, Mass. , July 24, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) generated net sales of $4.120 billion during the second quarter of 2024, growing 14.
5 percent on a reported basis, 16.1 percent on an operational 1 basis and 14.7 percent on an organic 2 basis, all compared to the prior year period.
The company reported GAAP net income attributable to Boston Scientific common stockholders of $324 million or $0.22 per share (EPS), compared to $261 million or $0.18 per share a year ago, and achieved adjusted 3 EPS of $0.
62 for the period, compared to $0.53 a year ago. "We delivered a quarter marked by exceptional performance, reflecting our global team's relentless pursuit of innovation that is supported by strong clinical evidence and investments aligned with our strategy of category leadership," said Mike Mahoney , chairman and chief executive officer, Boston Scientific.
"We remain excited about our plans for the future, and I am incredibly grateful for the commitment and winning spirit of our employees around the world." Second quarter financial results and recent developments: Reported net sales of $4.120 billion , representing an increase of 14.
5 percent on a reported basis, compared to the company's guidance range of 10.5 to 12.5 percent; 16.
1 percent on an operational basis; and 14.7 percent on an organic basis, compared to the company's guidance range of 10 to 12 percent, all compared to the prior year period. Reported GAAP net income attributa.